Evaluation of digestive proteinases from the Antarctic krill Euphasia superba as potential chemonucleolytic agents. In vitro and in vivo studies.
Chemonucleolysis is a therapeutic procedure whereby a degradative enzyme is injected intradiscally to reduce disc height/width by depolymerisation of extracellular matrix components. This process is considered to diminish disc pressure on inflamed nerve roots, resulting in the alleviation of sciatic pain. In the present study two krill (Euphasia superba) enzyme preparations, a proteinase and an esterase preparation, were evaluated for their potential as chemonucleolytic agents. Initially, their ability to degrade several protein (azocoll, casein, proteoglycans, PGs) and peptide (CBZ-arg-4-nitroanilide, CBZ-lys-thiobenzyl ester) substrates was assessed in vitro. The krill proteinase preparation rapidly converted azocoll, casein and PGs to small peptides. Furthermore, when this degradative enzyme preparation was evaluated in vivo, a relatively low intradiscal dose (0.54 mg/disc) was found to reduce intervertebral disc widths in beagles to 48% +/- 10.5% (mean +/- SEM) of their pre-injection values within 2 weeks of administration. Moreover, the discs injected with this proteinase had reconstituted up to 80% +/- 9% (mean +/- SEM) of their pre-injection widths at the termination of the experiment (32 weeks). These data suggest that the krill protease preparation has potential as a chemonucleolytic agent which would allow disc matrix reconstitution. Conversely, the krill esterase preparation also degraded PGs, but into relatively large fragments. This limited digestion of PGs indicates that the krill esterase would be a less effective chemonucleolytic agent than the corresponding proteinase.
Melrose
J
J
Raymond Purves Bone and Joint Research Laboratories, University of Sydney, New South Wales, Australia.
Hall
A
A
Macpherson
C
C
Bellenger
C R
CR
Ghosh
P
P
D000818:Animals; D001391:Azo Compounds / Q000378:metabolism; D002364:Caseins / Q000187:drug effects / Q000378:metabolism; D002863:Chromogenic Compounds / Q000378:metabolism; D003094:Collagen / Q000378:metabolism; D003445:Crustacea / Q000201:enzymology*; D004285:Dogs; D010450:Endopeptidases / Q000008:administration & dosage / Q000627:therapeutic use*; D004950:Esterases / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D066298:In Vitro Techniques; D015552:Injections, Intralesional; D007404:Intervertebral Disc Chemolysis; D008159:Lumbar Vertebrae / Q000187:drug effects*; D009930:Organic Chemicals; D011509:Proteoglycans / Q000187:drug effects / Q000378:metabolism
D001391:Azo Compounds; D002364:Caseins; D002863:Chromogenic Compounds; D009930:Organic Chemicals; D011509:Proteoglycans; C043626:hide powder azure; C028470:Azocoll; D003094:Collagen; D004950:Esterases; D010450:Endopeptidases